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ABSTRACT 24 
 25 
Medroxyprogesterone acetate (MPA) is a synthetic progestin commonly used in hormone 26 
replacement therapy (HRT). The aim of this work was to study and compare the effect of 27 
progesterone (Pg) and MPA, on the regulation of cellular events associated with vascular 28 
homeostasis and disease. Platelet adhesion to endothelial cells (ECs), nitric oxide (NO) 29 
production, and cell migration were studied using murine endothelial cells in vitro exposed to the 30 
progestins. After seven minutes treatment, MPA significantly inhibited NO synthesis with respect to 31 
control value; meanwhile Pg markedly increased vasoactive production. In senile ECs, the 32 
stimulatory action of Pg decreases; meanwhile MPA maintained its ability to inhibit NO 33 
synthesis.The presence of RU486 antagonized each steroid action. When ECs were preincubated 34 
with PD98059 (MAPK inhibitor) or chelerythrine (PKC inhibitor) before Pg or MPA treatment, the 35 
former totally suppressed the steroid action, but the PKC antagonist did not affect NO production. 36 
In the presence of a PI3K inhibitor (LY294002) a partial reduction in Pg effect, and a reversal of 37 
MPA action was detected. Using indomethacin the contribution of cyclooxygenase (COX) pathway 38 
was also detected. On platelet adhesion assays, Pg inhibited and MPA stimulated platelet 39 
adhesion to ECs. Under inflammatory conditions, Pg prevented platelet adhesion induced by 40 
lipopolysaccharide (LPS); meanwhile MPA potentiated the stimulatory action of LPS. Finally, 41 
although both steroids enhanced ECs migration, MPA exhibited a greater effect. In conclusion the 42 
data presented in this research provide evidence of a differential regulation of vascular function by 43 
Pg and MPA. 44 
 45 
Keywords: cell migration, medroxyprogesterone acetate, nitric oxide, progesterone, vascular 46 
tissue 47 
48 
Page 2 of 39
3 
 
INTRODUCTION 49 
 50 
The endothelium is the main regulator of vascular physiology that contributes to maintain vascular 51 
tone and non thrombogenic properties of endothelial surface. Endothelial NO is key factor of 52 
vascular homeostasis with antiatherogenic and antithrombotic properties. NO is a potent 53 
vasodilator which prevents platelet aggregation (Ignarro 1989) and leukocytes adhesion to the 54 
endothelium (Tsao et al. 1995), and decreases the expression of proinflammatory genes (Harrison 55 
et al. 2006). Several cardiovascular risk factors such as oxidative stress, alterations in plasmatic 56 
lipid profile, hypertension, viral infections, and diabetes mellitus, promote endothelial dysfunction 57 
and consequently vascular diseases, mainly atherosclerosis. The genesis of atheromatous lesions 58 
has a multifactorial pattern characterized by impaired synthesis of vasoactive molecules (NO and 59 
prostacyclin), enhanced synthesis and expression of cell adhesion molecules (CAMs) involved in 60 
leukocyte infiltration and platelet adhesion, as well as an altered profile of cell proliferation and 61 
migration. The initial response to vascular injury includes activation, adhesion, and aggregation of 62 
platelets to endothelium, events that release cytokines and enhance leukocyte recruitment (Ross 63 
1999). In vascular diseases, ECs turnover is altered (Choy et al. 2001). After endothelium damage, 64 
vessel repair is achieved by migration and proliferation of adjacent ECs (Cartwright et al. 2000; 65 
Moreno et al. 2009). 66 
Menopause hypoestrogenism represents a physiological risk factor for cardiovascular disease, fact 67 
attributed to the loss of 17β-estradiol (E2) cardioprotection. However, beside E2 circulating levels 68 
diminution, during menopause the ovarian synthesis of Pg is also affected. HRT based on 69 
estrogen, or combined with natural or synthetic progestins like MPA, emerges as an alternative to 70 
relieve the signs and symptoms associated with menopause. Although the large body of 71 
information derived from in vitro experimental studies that confer to E2 a relevant cardioprotective 72 
action, this cannot be translated into health benefit when HRT is applied to postmenopausal 73 
women. This raises the controversy about the risk/benefit of HRT on cardiovascular disease.  74 
Historically, progestins were included in the HRT protocols to counteract the endometrial dysplasia 75 
caused by E2. It has been reported that administration of MPA improves the effectiveness of HRT 76 
(Manson et al. 2003). However, other studies have shown that co-administration of progestins 77 
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blocks the atheroprotective effect of estrogen (Sitruk-Ware 2000). The secondary cardiovascular 78 
prevention study HERS (Heart and Estrogen/progestin Replacement Study) showed that HRT 79 
performed by oral administration of conjugated equine estrogen (CEE) and MPA for four years, 80 
was not able to reduce the incidence of coronary events, and in turn, increased the risk of 81 
thromboembolic events in postmenopausal women with established coronary artery disease 82 
(Grady et al. 2002; Hulley et al. 1998). Indeed, in the Women's Health Initiative (WHI) trial, CEE 83 
plus MPA administration to healthy postmenopausal women resulted in a substantial increase in 84 
risk of myocardial infarction (Rossouw et al. 2002). In contrast, another study also performed in 85 
healthy postmenopausal women showed that oral administration of E2 plus Pg, improved 86 
circulating levels of coagulation factors and vascular health (van Baal et al. 1999). 87 
Vascular function is regulated by several hormones and factors including sex steroids. Both, ECs 88 
and vascular smooth muscle cells (VSMCs) possess estrogen receptor and Pg receptor (PgR) 89 
(Joswig et al. 1999; Vazquez et al. 1999). Current knowledge about the biochemical action of 90 
natural Pg and other progestins at vascular level is quite low in contrast to the large amount of 91 
evidence reported to E2. In the last years, potential vascular effects of Pg have been described. In 92 
rabbit coronary arteries and rat aorta, Pg induces endothelium-independent vasorelaxation (Jiang 93 
et al. 1992). Moreover, Pg regulates vascular cells growth (Glusa et al. 1997; Simoncini et al. 94 
2003) and inhibits adhesion molecules expression induced by tumour necrosis factor-alpha (TNF-95 
α) and LPS (Glusa et al. 1997; Otsuki et al. 2001; Simoncini et al. 2004). We have previously 96 
demonstrated that in rat aortic tissue, Pg non genomically induces nitric oxide synthase (NOS) and 97 
COX stimulation through a mechanism of action that involves mitogen-activated protein kinase 98 
(MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways, and a cross-talk between 99 
NOS and COX systems. The rapid action of the steroid also includes an inhibition of platelet 100 
aggregation dependent on NOS and phospholipase C (PLC) transductions systems (Mendiberri et 101 
al. 2006). The fast effects elicited by the hormone are required for the regulation of ECs growth 102 
(Cutini et al. 2009). Pg also enhances cell proliferation, migration, and apoptosis of VSMCs. The 103 
regulation of muscle cell growth matched with the two step model of steroid action that integrates 104 
genomic and non genomic actions (Cutini et al. 2009; Cutini & Massheimer 2010). 105 
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There is evidence in the literature that Pg and MPA are not equivalent in terms of molecular 106 
signaling in human and murine vascular tissue. It has been reported that Pg and MPA activate 107 
different signaling events in vitro (L'hermite et al. 2008). MPA and other synthetic progestins exert 108 
different inflammatory and anti-inflammatory effects in vitro when compared with Pg (Simoncini et 109 
al. 2004). Therefore, the aim of this work was to study and compare the effect of Pg and MPA on 110 
the regulation of cellular events associated with vascular homeostasis and disease: platelet 111 
adhesion to ECs, NO production, and cell migration. 112 
 113 
MATERIALS AND METHODS 114 
Materials  115 
Pg was obtained from Calbiochem-Novabiochem International (San Diego, CA, USA). Griess 116 
reagents were purchased from Britania Laboratories (Buenos Aires, Argentina). Trypsin/EDTA 117 
(10×), l-glutamine (100×), amphotericin B (0.25 mg/mL), penicillin/streptomycin (100×), and fetal 118 
calf serum were obtained from PAA Laboratories (Pasching, Austria). Dulbecco’s modified Eagle’s 119 
medium (DMEM), MPA, N-nitro-L-arginine methyl ester (L-NAME), and all other reagents were 120 
purchased from Sigma Chemical Company (St Louis, MO, USA).  121 
 122 
Animals 123 
Young (3–5 weeks old) and old (24 months old) female Wistar rats were employed. They were fed 124 
with standard rat food, given water ad libitum and maintained on a 12 h light/12 h dark cycle. All 125 
the procedures were performed in accordance with the guidelines published in the National 126 
Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures involving 127 
animal and their care were performed at the Unit of Animal Care belonging to the Department of 128 
Biology, Biochemistry and Pharmacy at the University. The Animal Care Use Committee of this 129 
Unit approved the protocol used. 130 
The absence of ovarian activity in old female rats was performed by daily controls of oestrous cycle 131 
activity evaluated by optical microscope examination of vaginal smears. No estrous cycles were 132 
detected for at least 2-4 consecutive months (Selles et al. 2005). 133 
 134 
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ECs culture 135 
ECs cultures were obtained from aortic rings explants isolated from young Wistar female rats (3–5 136 
weeks old) (Yeh et al. 2002). When ECs of senile rats (senile ECs) were employed, aortic rings 137 
explants were isolated from aged Wistar rats (1.5–2 years old). Briefly, animals were killed by 138 
cervical dislocation and the full length thoracic aorta was aseptically removed. Immediately after, 139 
the aorta was cleaned of adherent connective tissue, and cut into small ring-shaped segments. 140 
Ring explants were seeded in a 60mm matrix-coated Petri dishes (NUNC) containing phenol red-141 
free DMEM supplemented with 20% (v/v) fetal calf serum (FCS), 60 µg/mL penicillin, 2.5 µg/mL 142 
amphotericin-B, 2 mM L-glutamine, and 1.7 g/L sodium bicarbonate. Explants were incubated at 143 
37ºC in 5% CO2 atmosphere. In order to establish a pure ECs culture, after three days of culture 144 
the ring explants were removed and ECs were allowed to reach confluence. The identity of the 145 
ECs was determined (a) by phase-contrast microscope observation of the characteristic 146 
morphology of cobblestone shape growth in confluent monolayer, (b) by positive 147 
immunocytochemistry reactivity to Factor VIII and to anti-Vimentin, clone V9 using 148 
DakoCytomation EnVision system, and (c) by the bioability to synthesize NO (Campelo et al. 149 
2012). Cells from passages 2–7 were used for all experiments. Fresh medium containing 10% (v/v) 150 
FCS was replaced every 72 h. Steroid solutions employed in the cellular treatments were prepared 151 
using isopropanol as solvent. The final concentration of the vehicle was always below than 0.1% 152 
(v/v). 153 
 154 
Hematoxylin and Eosin staining 155 
ECs were grown in 35 mm culture dishes (NUNC). Confluent ECs were washed twice with 156 
phosphate-buffered saline (PBS) and fixed with glutaraldehyde 0.1% (v/v). The cells were stained 157 
with hematoxylin and eosin solution. Images were recorded using a digital camera (Olympus 158 
C7070WZ) coupled to an optical microscope (Olympus BX51). 159 
 160 
Immunofluorescence detection of vascular endothelial growth factor receptor 2 (VEGFR2) 161 
and CD34 expression 162 
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ECs were grown in 96-well optical bottom plates (NUNC). Confluent ECs were washed twice with 163 
PBS and fixed with paraformaldehyde 2% (v/v) in PBS for 15 minutes. Then cells were 164 
permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 minutes, and incubated with 1% albumin 165 
for 1 hour to prevent non-specific antibody binding. Cells were immunostained with anti-CD34 166 
(8G12 BD Biosciences) or anti-VEGFR2 (FAB357P BD Biosciences). Cell nuclei were 167 
counterstained with 4-6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Immunofluorescence 168 
was visualized using an Olympus BX51 microscope equipped with a Q-Color 3 digital camera 169 
(Olympus America, Center Valley, PA). 170 
 171 
Platelet assays 172 
Platelet isolation 173 
For platelet aggregation assays, rat platelet-rich plasma (PRP) was obtained as previously 174 
described (Cutini et al. 2012). For platelet adhesion assays, PRP was fixed in 4% (v/v) 175 
formaldehyde/PBS for 10 minutes, suspended in PBS (pH 7.4) at room temperature and 176 
centrifugated at 750 × g for 10 minutes. Then, fixed platelets were washed twice with PBS. Manual 177 
platelet count was done using a hemacytometer. Finally, platelets were suspended at a final 178 
concentration of 5×106 platelets/mL in DMEM supplemented with 1% (v/v) FCS. 179 
 180 
Platelet adhesion assay 181 
Confluent monolayers of ECs seeded on 24-multiwell culture plates (NUNC) were starved for 24 h 182 
with serum-free DMEM, and then exposed to Pg, MPA, LPS (1 µg/mL) or steroids plus LPS in 183 
DMEM supplemented with 1% (v/v) FCS. Once finished treatment, ECs were washed two times 184 
with PBS, and 300 µL of platelet suspension were added on pretreated cells. Platelets were 185 
allowed to adhere to ECs for 2 h at 37ºC. Supernatants of each well containing non-adhered 186 
platelets were collected and counted employing a hemacytometer. The number of adhered 187 
platelets to ECs was calculated by difference between total added platelets and non-adherent 188 
platelets. Results are expressed as mean ± SD of the number of adhered platelets/µL. 189 
 190 
Platelet aggregation assay 191 
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Platelet aggregation was measured using a turbidimetric assay as previously described (Cutini et 192 
al. 2012). ECs were seeded on 24-multiwell culture plates (NUNC) at a density of 3×104 cells/well 193 
in DMEM supplemented with 10% (v/v) FCS and allowed to grow to 60–70% of confluence. Culture 194 
medium was replaced by 400 µl of PRP, 3×108 platelets/mL) and exposed to 10 nM Pg, 10 nM 195 
MPA or vehicle (control) for 5 minutes. Immediately after treatment, 285 µl of PRP was taken and 196 
set in a CronoLog 430 aggregometer cuvette with continuous stirring. Aggregation was initiated by 197 
the addition of 2×10-5 M adenosine diphosphate (ADP). Control group containing ECs in PRP was 198 
treated with vehicle alone (isopropanol <0.1%, v/v). Changes in light transmission were recorded 199 
for 5 minutes after ADP addition. The signal generated by a platelet-poor plasma was taken as 200 
100% transparent control (Kikuta et al. 1998). ECs were dissolved in 1 M NaOH and aliquots were 201 
taken for protein determination by Lowry’s method. Results were expressed as percentage of 202 
inhibition of platelet aggregation with respect to control. The maximal platelet aggregation was 203 
considered to be that induced by the control samples. Two animals were used for each 204 
experiment. When the direct effect of the progestins on platelets were evaluated, PRP was 205 
incubated with the Pg or MPA in the absence of ECs, and platelet aggregation was measured as 206 
described above. Basal aggregation was considered the maximal aggregation exhibited by PRP 207 
alone, without vehicle or steroid treatment. Results were expressed as percentage of platelet 208 
aggregation with respect to basal. 209 
 210 
Measurement of NO production  211 
ECs were seeded on 24-multiwell culture plates (NUNC) at a density of 3.5×104 cells/well and 212 
allowed to grow to 90% of confluence in DMEM containing 10% (v/v) FCS. Steroid treatment was 213 
performed in fresh DMEM containing 1% (v/v) FCS by addition of Pg or MPA for 7 minutes. 214 
Respective controls (vehicle alone) were also processed. When specific antagonist/inhibitors were 215 
used, they were added 30 minutes before steroid treatment. Nitrites (NO2
−) were measured in the 216 
incubation media as a stable and non-volatile breakdown product of the NO released, employing 217 
the spectrometric Griess reaction (Campelo et al. 2012). Briefly, once finished treatment, aliquots 218 
of culture medium supernatant were mixed with Griess reagent (1% sulphanilamide and 0.1% 219 
naphthylenediamine dihydrochloride in 2.5% phosphoric acid) and incubated 10 minutes at room 220 
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temperature. Absorbance was measured at 548 nm in a microplate reader (Biotek Synergy-HT). 221 
The concentration of NO2
− in the samples was determined with reference to a sodium nitrite 222 
(NaNO2) standard curve performed in the same matrix. Cells were dissolved in 1 M NaOH, and 223 
protein content was measured by Lowry Method (Lowry et al. 1951). The results were expressed 224 
as nmol of NO2
− per mg protein.  225 
 226 
Cell migration assay  227 
Cells were seeded at a density of 5×105 cells/cm2 in 60mm NUNC dishes with DMEM containing 228 
10% (v/v) FCS, and were grown to 90% confluence. Cells were starved for 24 h with serum-free 229 
medium. In order to evaluate cell migration, a wound was made by pressing a razor blade down on 230 
the dish and remove part of the monolayer (Pedram et al. 2002). Immediately after, adhered cells 231 
were washed twice with PBS and cultured in fresh DMEM containing 1% (v/v) FCS plus Pg, MPA 232 
or vehicle control. After 48 h of culture, cells were fixed with glutaraldehyde 0.1% (v/v) and stained 233 
with Giemsa solution. Migration was quantified by counting the number of cell nuclei that migrated 234 
at scratched area in at least seven different representative fields of each culture plate. Cell 235 
migration was recorded using a digital camera (Olympus C7070WZ) coupled to an optical 236 
microscope (Olympus BX51). Results are expressed as mean ± SD of the number of migrated 237 
cells/field. 238 
 239 
Crystal Violet assay 240 
Endothelial cells were seeded on 96-multi-well plates (NUNC) at a density of 5×103 cells/well in 241 
DMEM supplemented with 10% (v/v) FCS and allowed to grow to 60–70% confluence. Cells were 242 
synchronized by placing in serum-free DMEM for 24 h, and further exposed to different 243 
concentrations of Pg, MPA or vehicle (control) for 24 h in fresh DMEM containing 1% (v/v) FCS. 244 
Medium was removed, the cells were fixed in 1% glutaraldehyde for 15 minutes and subsequently 245 
stained for 30 minutes in 0.1% crystal violet. Immediately after, the cells were washed twice, air-246 
dried, and dissolved in 0.2 % triton. Absorbance of each well was measured at 590 nm in a 247 
microplate reader (Biotek Synergy-HT). Cell viability was determined as optical density (OD) 248 
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increase, and maximal viability was considered the OD registered from control group. Results are 249 
expressed as percentage of cell viability with respect to control.  250 
 251 
Statistical analysis 252 
The results presented were obtained from three independent experiments where each individual 253 
experimental condition was performed by quadruplicate (n=4). All data are presented as mean ± 254 
SD. Different cell cultures were used for each independent experiment. Comparisons between two 255 
means were made using Student’s t-test, and multiple comparisons with one or two ways ANOVA, 256 
followed by Fisher’s least significant difference test, using SSPS Statistical software for Windows. 257 
P-values lower than 0.05 were considered to be statistically significant. 258 
 259 
RESULTS 260 
Having in mind our previous reports in rat aortic tissue concerning the non-genomic action of Pg on 261 
NO synthesis (Cutini et al. 2009; Mendiberri et al. 2006; Selles et al. 2002), using isolated ECs we 262 
studied the rapid regulation of NO production by different concentrations of Pg and MPA. To that 263 
end, cells were exposed to Pg or MPA for 7 minutes. Fig. 1A shows that MPA treatment 264 
significantly inhibited NO synthesis with respect to control value (43, 40, and 49% below control; 1, 265 
10, and 100 nM MPA respectively; P<0.02). On the other hand, when ECs were treated with the 266 
same concentrations of Pg, a marked stimulus in the vasoactive synthesis was detected (41, 64, 267 
and 96% above control; 1, 10, and 100 nM Pg respectively; P<0.02) (Fig. 1A). In order to 268 
determine whether Pg and MPA were affecting NOS derived NO, we measured the rapid 269 
production of NO in the presence of an irreversible NOS inhibitor (L-NAME). As shown in Fig. 1A, 270 
10 µM L-NAME, completely suppressed the effects evoked by the progestogens. 271 
The effect of Pg and MPA on ECs viability was evaluated using crystal violet assay. The results 272 
presented in Table 1 show that maximal cell viability was observed in all experimental conditions, 273 
ruling out a negative effect of progestins on cell survival. 274 
The effects of Pg and MPA were also tested in ECs isolated from senile rats devoid of ovarian 275 
activity. The stimulatory action of Pg markedly decreased; meanwhile MPA maintained its ability to 276 
inhibit NO synthesis (Fig. 1B). Negative controls with L-NAME were also performed. We also 277 
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checked the existence of phenotypic differences between young and senile derived ECs. Fig. 2 278 
shows that, similar morphological features (hematoxylin and eosin staining) and comparable ECs 279 
markers expression (VEGFR2; CD34) were found in both groups. 280 
In order to evaluate the participation of PgR on the steroids effect on NO production, we employed 281 
an antagonist of PgR, the compound RU486. ECs were preincubated 30 minutes with 1 µM RU486 282 
prior to steroid treatment. We obtained evidence that the antagonist affected either the fast 283 
stimulatory or the inhibitory action on NO production exerted by Pg or MPA respectively (Fig. 3). 284 
The presence of the PgR antagonist partially suppressed the stimulatory action of Pg on NO 285 
synthesis (64 and 96% vs 35 and 47% above control, Pg 10 and 100 nM in the absence vs 286 
presence of RU486, respectively, P<0.05) (Fig. 3). Similar results were obtained when the cells 287 
were treated with 1 nM Pg or 1 nM MPA (data not shown). Simultaneous preincubation of ECs with 288 
RU486 and L-NAME prior to hormonal treatment, blunted NO production (Fig. 3). We also evaluate 289 
the probable participation of androgen receptor (AR) using flutamide as AR antagonist. The 290 
presence of flutamide did not affect progestins action on NO synthesis (data not shown). 291 
The involvement of protein kinase C (PKC), MAPK, and PI3K intracellular signaling transduction 292 
pathways, on Pg and MPA regulation of vasoactive production was investigated. To that end, ECs 293 
were preincubated 30 minutes in the absence or presence of LY294002 (PI3K inhibitor), PD98059 294 
(MAPK inhibitor) or chelerythrine (PKC inhibitor) before treatment with Pg or MPA.  295 
The MEK (mitogen-activated protein kinase kinase) inhibitor (PD98059) totally abolished the 296 
stimulatory action on NO synthesis elicited by 10 nM Pg (Fig. 4A). On the other hand, the inhibition 297 
of PKC signaling pathway with chelerythrine did not modify the stimulation on NO production 298 
induced by the natural progestogen. Meantime, a partial reduction in Pg effect was observed in the 299 
presence of LY294002 (Fig. 4A). Similar results were obtained when hormonal treatments were 300 
performed with 1 or 100 nM Pg, or in the presence of other PI3K inhibitor (wortmannin) (data not 301 
shown). 302 
As we can be seen in Fig. 4B, the presence of PD98059 or LY294002 completely suppressed the 303 
inhibitory effect on NO production exerted by 10 nM MPA treatment. Noteworthy that, the presence 304 
of the PI3K pathway inhibitor, not only completely abolished the inhibitory effect of MPA on 305 
vasoactive synthesis but also enhanced NO production with respect to control. As observed with 306 
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Pg treatment, when ECs were pretreated with the PKC inhibitor, the action of 10 nM MPA was not 307 
modified (Fig. 4B). Similar results were obtained when ECs treatment was performed with 1 or 100 308 
nM MPA (data not shown). Again, the negative control performed using L-NAME confirmed the 309 
progestin’s actions on NOS derived NO (Fig. 4A and 4B). 310 
Having in mind that our previous work demonstrated that in rat aortic strips Pg mechanism of 311 
action is dependent on a cross talk between COX and NOS pathways that involves COX 312 
stimulation for NOS synthesis (Selles et al. 2002), we performed additional experiments to test 313 
whether, in isolated ECs the effect of progestins on NO production is dependent on COX activity. 314 
To that end, indomethacin was used as COX inhibitor. As can be observed in Fig. 5 pretreatment 315 
with indomethacin reversed the effect of Pg or MPA on NO synthesis. 316 
Since NOS and COX end products can affect platelet function, In order to study whether the 317 
steroids were able to regulate platelet-ECs interactions, platelet adhesion and platelet aggregation 318 
assays were performed. Cells were incubated with Pg or MPA for 24 h in the presence or absence 319 
of a platelet adhesion inductor, bacterial LPS, which was added during the last 21 h of steroid 320 
treatment. Once treatment was finished, an exact number of platelets was seeded on ECs 321 
monolayers and allowed to adhere for 2 h. Fig. 6A shows that treatment with Pg (1, 10, and 100 322 
nM) significantly inhibited platelet adhesion to ECs with respect to the control (29, 26, and 22% 323 
below control; Pg 1, 10, and 100 nM respectively; P<0.05). On the other hand, when cells were 324 
exposed to LPS, platelet adhesion was markedly increased (69% above control, P<0.001). 325 
However, pre-treatment of ECs with 1, 10, and 100 nM Pg, totally abolished platelet adhesion 326 
induced by the proinflammatory agent (Fig. 6A). By contrast, treatment of cells with 1, 10, and 100 327 
nM MPA significantly increased platelet adhesion (33, 37, and 44% above control; MPA 1, 10, and 328 
100 nM respectively; P<0.05) (Fig. 6B). Moreover, we can see that, unlike Pg results, pre-329 
treatment of cells with MPA, potentiated the stimulatory action of LPS on platelet adhesion (Fig. 330 
6B).  331 
To test the effect of the progestins on platelet aggregation, ECs were incubated with PRP and 332 
subsequently exposed to Pg or MPA for 5 minutes. Immediately, aliquots of PRP were transferred 333 
to the aggregometer and ADP-induced platelet aggregation was measured. Table 2 shows the 334 
quantitative data obtained. Similarly as our previous data obtained with rat aortic strips  (Sellés et 335 
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al, 2002), Pg exhibited a markedly antiaggregatory action, meanwhile the inhibition of platelet 336 
aggregation (IPA) induced by MPA was lower (82.3 vs 27.2% IPA with respect to control, Pg vs 337 
MPA). A direct action of the progestins on platelets was ruled out, since the addition of Pg or MPA 338 
to PRP in the absence of ECs, induced maximal aggregation similar to basal group (Table 2). 339 
Afterwards, using wound healing assays, we examined the effect of Pg and MPA on ECs 340 
migration. Fig. 7 shows that 48 h treatment with Pg induced a significant enhance in the number of 341 
cells that cross the wound border and migrated to removed area in a wide range of concentrations 342 
tested (5-100 nM). At lower doses (1 nM Pg) no significant differences were detected in the 343 
number of migrant cells with respect to the control group (Fig. 7). 344 
When the synthetic progestin was assayed, the evidence shows that MPA also increased cell 345 
migration to denuded area compared to non-treated cells at all concentrations tested (Fig. 8).  346 
The magnitude of the incremental increase induced by MPA was much higher than the stimulatory 347 
action elicited by Pg (1168% vs 275%; 10 nM MPA vs 10 nM Pg respectively, P<0.001) (Fig. 7 and 348 
Fig. 8).  349 
Finally, Fig. 9 shows a schematic diagram that summarise the results obtained. 350 
DISCUSSION  351 
The data presented in this research provide evidence of a differential regulation of vascular 352 
function by Pg and MPA. Pg markedly stimulates NO production; meanwhile MPA inhibits its 353 
synthesis. Although Pg and MPA exhibit divergent effects on the vasoactive generation, both 354 
mechanisms of action involve at least in part, the participation of PgR; COX; PI3K; and MAPK 355 
signal transduction pathways. Under inflammatory conditions Pg prevents platelet adhesion to 356 
ECs. In contrast, MPA potentiates platelet adhesion. Both steroids enhance cell migration in a wide 357 
range of concentration.  358 
Divergent actions of Pg and MPA have been previously shown using human umbilical vein 359 
endothelial cells (HUVECs) (Simoncini et al. 2004). In contrast, having in mind that atherosclerosis 360 
mainly affect arteries, we focused our attention on the progestins vascular actions on aortic ECs. 361 
Endothelial NO bioavailability plays a pivotal role in the maintenance of vascular homeostasis. 362 
Impairment of NO production seriously compromises vascular health and represents a risk factor 363 
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for disease development (Duckles & Miller 2010). We showed that, Pg and MPA have opposite 364 
effects on NO production in ECs. Physiological concentrations of Pg rapidly stimulate, whereas 365 
MPA inhibits NO production. The blockage of progestin’s effects with L-NAME confirms that Pg 366 
and MPA are affecting NOS derived NO. Evidence reported in the literature shows that Pg 367 
increases NO synthesis in human ECs by transcriptional and non-transcriptional mechanisms, 368 
whereas MPA lacks such actions (Simoncini et al. 2006). Furthermore, chronic administration of Pg 369 
to ovariectomized rats restores the endothelial control of vascular tone in mesenteric arterial rings 370 
through the endothelial formation of NO, meanwhile MPA failed to do that (Chataigneau et al. 371 
2004). On this line of evidence, we found that in ECs isolated from rats devoid of ovarian activity, 372 
MPA maintained its inhibitory action on NOS synthesis. 373 
It is known that blood vessels express functional PgR (Perrot-Applanat et al. 1988), which would 374 
be regulated by Pg as well as by synthetic progestins, like MPA (Sitruk-Ware 2000). The 375 
involvement of PgR on cellular and molecular effects of MPA and Pg at the vascular level has been 376 
reported. In HUVECs, the PgR antagonist RU486 caused reduction of the inhibitory action of MPA 377 
on the E2-induced endothelial NOS (eNOS) phosphorylation and eNOS activity (Oishi et al. 2011). 378 
In HUVECs, Pg and MPA decreased thromboxane A2 release, and enhanced prostacyclin 379 
synthase gene and protein expression in a PgR-dependent manner (Oviedo et al. 2011). MPA 380 
antagonizes the E2-stimulation of vascular endothelial growth factor (VEGF) expression in human 381 
endometrial stromal cells through a mechanism of action that involves the PgR (Okada et al. 382 
2011). Using RU486 as PgR antagonist, we obtained evidence that PgR participates in the fast 383 
action of both steroids on NO synthesis regulation, with slight differences. The decrease in NO 384 
production induced by MPA was completely abolished by the RU486 compound. However, the 385 
enhancement in the vasoactive release elicited by Pg was partially dependent on PgR. Although 386 
this evidence suggests the participation of PgR on opposite effect on NO production, it remains to 387 
determine whether the steroids effects involve the isoforms A or B of PgR, as well as the possible 388 
participation of a membrane-anchored receptor, which has been recently described (Zhu et al. 389 
2003).  390 
The activity of eNOS is regulated by changes in intracellular calcium and phosphorylation. After 391 
agonist stimulation, the enhancement in cytosolic calcium leads to calmodulin binding to eNOS and 392 
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subsequent phosphorylation. The enzymes responsible for phosphorylation status depend on the 393 
primary stimulus. Several intracellular signaling systems, such as AC/PKA, PLC/PKC, PI3K/Akt, 394 
CaMKII, and MAPK, have been involved in the hormonal regulation of eNOS activity (Forstermann 395 
2010). Indeed, protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) also participate 396 
(Ladurner et al. 2012). Employing selective kinase inhibitors we found that the mechanism of 397 
action displayed by Pg and MPA on the regulation of endothelial NO production was dependent on 398 
MAPK pathway, and independent of PKC activation. Indeed, PI3K was partially involved in Pg 399 
action; meanwhile the presence of LY294002 not only suppressed the inhibitory effect of MPA but 400 
also enhanced the NO synthesis with respect to control. In hippocampal neurons, both Pg and 401 
MPA activate p44/p42MAPK (ERK) signaling pathway, Pg quickly and transiently activates nuclear 402 
ERK, while MPA-activated ERK remains cytosolic without nuclear signal (Nilsen & Brinton 2003). 403 
MPA induces cell proliferation through up-regulation of cyclin D1 expression via PI3K/Akt/NF-kB 404 
cascade in human breast cancer cells (Saitoh et al. 2005), or drives PgR to interact with tyrosine 405 
kinase c-Src and to activate PI3K signaling pathway, leading to the activation of RhoA/ROCK-2 406 
signaling system (Fu et al. 2008b). In human ECs, it has been reported divergent effects of MPA 407 
and Pg with a patent difference in the recruitment of MAPK and PI3K signal transduction pathways 408 
(Simoncini et al. 2006). Taking in account that we have previously reported that Pg stimulates COX 409 
activity, we also tested the feasible participation of COX system on Pg and MPA action on NO 410 
production. Cross talk between NOS and COX systems has been proposed. Although there is a 411 
plethora of evidence in the literature suggesting that increased NO stimulates COX-2, the 412 
interaction between NO and prostaglandin is not unidirectional and upregulation of NOS activity by 413 
COX has been also reported (Kim 2011; Salvemini 1997). In rat Kupffer cells and in platelets, 414 
indomethacin significantly reduced NOS activity (Gaillard et al. 1992; Chen et al. 1997). Our data 415 
suggest that the same intracellular pathways are implicated in opposite effects on NO synthesis 416 
elicited by each progestin. Based on the results obtained, a possible explanation for the 417 
mechanism of action involved would be that, MAPK and PI3K regulate NOS activity directly or 418 
through the modulation of COX activity. However, the results presented in this work cannot 419 
establish the sequence of the signal transduction pathways activation. It has been reported that in 420 
HUVECs and in brain microvascular ECs, PI3K/Akt and MAPK pathways are involved in COX 421 
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expression and activation (Garonna et al. 2011; Hsieh et al. 2012). Indeed, in HUVECs cells MPA 422 
stimulates COX activity (Hermenegildo et al. 2005). Having in mind the complexity of the 423 
intracellular signaling system, with multiple network interconnections between the different routes, 424 
a cross talk between different signal transduction pathways that eventually leads to the activation 425 
or inhibition of eNOS may occur. Moreover, considering that we have previously demonstrated that 426 
PP1 and PP2A participate in the non genomic action of Pg in rat aortic rings (Mendiberri et al. 427 
2006; Cutini et al. 2009), the possible participation of phosphatase pathways should not be ruled 428 
out. Further experiments are required to fully understand the signaling pathways involved in 429 
progestins NOS regulation. 430 
When the effect of the progestins on platelet-ECs interaction was evaluated, we found that Pg 431 
exerts an inhibitory effect on platelet adhesion to the endothelium, and in turn prevents the 432 
adhesion induced by an inflammatory environment (presence of LPS). Pg also exerts a potent 433 
antiaggregatory effect. Thus, the action of Pg may be considered a beneficial fact that contributes 434 
to avoid the earlier stage of vascular injury. On the other hand, we suggest that the synthetic 435 
progestin is associated with a potentially pro-atherogenic effect, since MPA stimulates platelet 436 
adhesion and also potentiates the effect exerted by the presence of LPS, and exhibited a slight 437 
antiaggregatory action compared to Pg. These results represent the first evidence of a direct action 438 
of MPA on platelet-ECs interactions. The data obtained in platelet aggregation assays suggest that 439 
the progestins indirectly modulate platelet aggregation through each direct action on ECs, probably 440 
due to the regulation of ECs release of proaggregatory or antiaggregatory vasoactives, such as 441 
thromboxane; NO, prostacyclin, that modulate platelet function. The findings that the mechanism of 442 
action elicited by each progestin involves NOS and COX transduction systems may support this 443 
interpretation. Platelet and monocyte adhesion to endothelium are events modulated through the 444 
expression of CAMs. It has been reported that in HUVECs, Pg prevents the expression of the 445 
protein and mRNA of TNF-α-induced vascular cell adhesion molecule-1 (VCAM-1), but MPA does 446 
not reverse the action of TNF-α (Otsuki et al. 2001). In peripheral and cerebral vasculature, MPA 447 
causes endothelial disruption, accumulation of monocytes in the vessel wall, and platelet 448 
activation, meanwhile, Pg does not show such toxicity (Thomas et al. 2003).  449 
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ECs proliferation and migration contribute to the development of new capillaries, tissue remodelling 450 
and repair. Using wound healing assays we demonstrated that Pg and MPA stimulate ECs 451 
migration to the denuded area, in a wide concentration range. In agreement with our results, Fu et 452 
al. showed that Pg and MPA enhance ECs migration via the actin-binding protein moesin (Fu et al. 453 
2008a). Moreover, Pg promotes ECs movement via the rapid regulation of the focal adhesion 454 
kinase (FAK) (Zheng et al. 2012). In breast cancer Pg and MPA promote cell movement via rapid 455 
actin cytoskeleton remodelling, which are mediated by moesin activation, events triggered by the 456 
extra-cellular small GTPase RhoA/Rho-associated kinase (ROCK-2) cascade through partially 457 
differing pathways by both steroids (Fu et al. 2008b).  458 
Link between NO production and cell migration has been reported. NO stimulates human neural 459 
progenitor cell migration via cGMP-mediated signal transduction (Tegenge et al. 2011). Moreover, 460 
NO is critically involved in human ECs migration (Schwalm et al. 2010). In contrast, plasma β₂-461 
glycoprotein I inhibits ECs migration through eNOS activation (Chiu et al. 2012). Although MPA 462 
and Pg have opposite effects on NO generation, they exhibit similar effects on ECs migration. The 463 
explanation for this dual effect remains to be established. 464 
Summing up, the results discussed in this paper contribute to provide information for the 465 
comprehension of Pg and MPA regulation of relevant cellular and molecular events of vascular 466 
homeostasis. Although it has been assumed that some synthetic progestins used in HRT protocols 467 
exert similar clinical actions than natural Pg, both progestogens elicit specific cellular effects. The 468 
different pharmacokinetics of natural or synthetic progestins and their diverse affinities for the PgR 469 
may lead to the recruitment of partially divergent signaling pathways due to differential modulation 470 
of the receptor. The evidence reported to date on the true role of natural Pg and its potential 471 
clinical utility is insufficient and unravelling its mechanism of action remains a challenge. Further 472 
investigations are required for a complete understanding of the similarities or divergences of 473 
natural and synthetic progestins vascular actions. 474 
475 
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FIGURE LEGENDS 651 
 652 
Figure 1 653 
Effect of Pg and MPA on NO production in ECs. Starved ECs (A) and senile ECs (B) were 654 
preincubated 30 minutes in the absence or presence of 10 µM L-NAME, and then treated with Pg 655 
or MPA at the indicated concentrations for 7 minutes. NO production was measured by Griess 656 
reaction as described in Materials and methods section. Results represent the average ± SD of 657 
three independent experiments (n=4). (C= control). *P<0.02 vs control. 658 
 659 
Figure 2. Characterization of ECs derived from young and senile rats. 660 
Microphotographs show representative fields of ECs obtained from young or adult (senile) rats 661 
immunostained with anti-CD34 (1 and 2); anti-VEGFR2 (3 and 4) or stained with hematoxylin and 662 
eosin (5 and 6). Cell nuclei were counterstained with DAPI (1-4). Details are described in Materials 663 
and methods section. Magnification: 600X (1-4) and 100X (5 and 6). The scale bar in 1-4 664 
represents 25 µm. The scale bar in 5 and 6 represents 100 µm. 665 
 666 
Figure 3 667 
Effect of a PgR antagonist on the regulation by Pg and MPA of NO production. Starved ECs 668 
were preincubated 30 minutes in the absence or presence of 1 µM RU486 or 1 µM RU486 plus 10 669 
µM L-NAME, and then exposed to Pg or MPA at the indicated concentrations for 7 minutes. NO 670 
production was measured by Griess reaction as described in Materials and methods section. 671 
Results represent the average ± SD of three independent experiments (n=4). (C= control). *P<0.02 672 
vs control plus vehicle; §P<0.01 vs each Pg; ‡P<0.05 vs control + RU486, †P<0.01 vs each MPA. 673 
 674 
Figure 4 675 
Involvement of MAPK, PI3K, and PKC signaling pathways on the regulation of NO 676 
production by Pg and MPA. Starved ECs were preincubated 30 minutes in the absence or 677 
presence of 5 µM PD98059, 1 µM LY294002, 1 µM chelerythrine, 10 µM L-NAME, and then 678 
exposed to 10 nM Pg (A) or 10 nM MPA (B) for 7 minutes. NO production was measured by Griess 679 
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reaction as described in Materials and methods section. Results represent the average ± SD of 680 
three independent experiments (n=4). (C= control). *P<0.02 vs control; §P<0.01 vs Pg; †P<0.01 vs 681 
control + LY294002; ¶P<0.02 vs control + chelerythrine; ‡P<0.01 vs MPA. 682 
 683 
Figure 5 684 
Involvement of COX signaling pathway on the regulation of NO production by Pg and MPA. 685 
Starved ECs were preincubated 30 minutes in the absence or presence of 10 µM indomethacin 686 
(INDO), and then exposed to 10 nM Pg (A) or 10 nM MPA (B) for 7 minutes. NO production was 687 
measured by Griess reaction as described in Materials and methods section. Results represent the 688 
average ± SD of three independent experiments (n=4). (C= control). *P<0.02 vs control; †P<0.01 689 
vs Pg; §P<0.01 vs control plus indomethacin; ‡P<0.01 vs MPA. 690 
 691 
Figure 6 692 
Effect of Pg and MPA on platelet adhesion to ECs. ECs cultures were treated with Pg (A) or 693 
MPA (B) at the indicated concentrations for 24 h in the presence or absence of 1 µg/mL LPS, 694 
which was added during the last 21 h of hormonal treatment. Platelets were seeded on ECs 695 
monolayer for 2 h. Immediately after, the supernatant was removed and the platelets were counted 696 
as described in Materials and methods section. Bars represent the means ± SD of the number of 697 
adhered platelets/µL. Results are the average ± SD of three independent experiments (n=4). 698 
*P<0.05 vs control; **P<0.001 vs control; †P<0.005 vs LPS; ‡P<0.02 vs LPS; §P<0.001 vs each 699 
MPA. 700 
 701 
Figure 7 702 
Effect of Pg on ECs migration. Confluent ECs cultures were serum starved for 24 h, and cells 703 
were removed by scraping. Detached cells were washed with PBS, and the remaining monolayer 704 
was treated during 48 h with Pg at the indicated concentrations or vehicle (control). Dotted lines 705 
indicate the boundary between the unscratched and scratched areas. (A) Images show 706 
representative fields of each condition after Giemsa staining (40X magnification).The scale bar 707 
represents 300 µm. (B) Bars show the means and standard deviations of number of migrated 708 
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cells/field from three separated experiments performed by quadruplicate. *P<0.001 vs control; 709 
§P<0.01 vs control. 710 
 711 
Figure 8 712 
Effect of MPA on ECs migration. Confluent ECs cultures were serum starved for 24 h, and cells 713 
were removed by scraping. Detached cells were washed with PBS, and the remaining monolayer 714 
was treated during 48 h with MPA at the indicated concentrations or vehicle (control). Dotted lines 715 
indicate the boundary between the unscratched and scratched areas. (A) Images show 716 
representative fields of each condition after Giemsa staining (40X magnification).The scale bar 717 
represents 300 µm. (B) Bars show the means and standard deviations of number of migrated 718 
cells/field from three separated experiments performed by quadruplicate. *P<0.001 vs control. 719 
 720 
Figure 9. Schematic representation of differential regulation of vascular function elicited by 721 
Pg and MPA. Pg stimulates while MPA inhibits endothelial NO production. The mechanisms of 722 
action involve PI3K, MAPK, and COX signal transduction pathways and PgR participation. The 723 
subtype of PgR involved remains to be established. Pg inhibits platelet aggregation and adhesion 724 
to CEs, whereas MPA stimulates platelet-ECs interactions. NO generated by the ECs diffuses to 725 
the tunica media in order to regulate vascular tone, or may be released to the vascular lumen 726 
affecting platelet function. (COX: cyclooxygenase; PgR: progesterone receptor; NO: nitric oxide). 727 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Table 1. Effect of Pg and MPA on ECs viability. 
 
cell viability  
(% respect to control)a 
Treatment  
1 nM Pg 99.8 ± 8.9 
10 nM Pg 102.4 ± 7.4 
100 nM Pg 90.15 ± 6.3 
1 nM MPA 101.8 ± 5.9 
10 nM MPA 103.4 ± 5.4 
100 nM MPA 98.5 ± 6.3 
 
a Subconfluent ECs were incubated in serum-free medium for 24 h and then treated with 
different concentrations of Pg, MPA or vehicle (control group) for additional 24 h in fresh 
DMEM containing 1% (v/v) FCS. Cell viability was measured by Crystal Violet assay as 
described in Material and Methods section. The optical density (OD) value in the control 
group is considered as 100%. Values are the average ± S.D. of three independent 
experiments performed by quadruplicate.  
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Table 2. Effect of Pg and MPA on platelet aggregation. 
Treatment 
Percentage of inhibition 
of platelet aggregation 
with respect to controla 
Percentage of platelet 
aggregation with respect to 
basalb 
10 nM Pg 82.3 ± 6.2* 97.5 ± 6.5 
10 nM MPA 27.2 ± 2.3‡ 98.2 ± 7.3 
 
*P<0.01 with respect to control and ‡P<0.05 with respect to control. 
aCulture medium was replaced by PRP and cells were exposed to 10 nM Pg, 10 nM MPA, 
or vehicle (control) for 5 minutes. PRP was rapidly removed and platelet aggregation was 
measured as described in Material and Methods section. Results are expressed as 
percent of inhibition of platelet aggregation with respect to control group (ECs plus vehicle 
alone) and are the average ± S.D. of three independent experiments (n=4). 
bAliquots of PRP (in the absence of ECs) were incubated with 10 nM Pg or 10 nM MPA for 
5 minutes. Basal group received vehicle alone. Immediately after ADP was added, platelet 
aggregation was measured. Results are expressed as percentage with respect to basal 
aggregation and represent the average ± S.D. of three independent experiments (n=4). 
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